| Literature DB >> 1485012 |
A Göcmen1, M F Toppare, N Kiper, N Büyükpamukcu.
Abstract
A diphosphonate, disodium etidronate, a compound known to inhibit microcrystal growth of hydroxyapatite was given to a 3.5-year-old girl with pulmonary alveolar microlithiasis (PAM) that was symptomatic. The drug was used for approximately 36 months in a single daily dose of 15 mg/kg. No significant side effects were encountered with somewhat clearing of lung bases in chest radiograms and subjective improvement in general condition. These findings suggest a role of diphosphonates in the treatment of PAM.Entities:
Mesh:
Substances:
Year: 1992 PMID: 1485012 DOI: 10.1159/000196068
Source DB: PubMed Journal: Respiration ISSN: 0025-7931 Impact factor: 3.580